Effect of discounting on estimation of benefits determined by hepatitis C treatment

World Journal of Gastroenterology

Volumn 18, Issue 23, 2012, Pages 3032-3034

  Messori, Andrea ^a   Fadda, Valeria ^b   Maratea, Dario ^b   Trippoli, Sabrina ^a  

^a Laboratorio SIFO di Farmacoeconomia   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Boceprevir; Cost effectiveness; Hepatitis C; Markov model; Telaprevir

Indexed keywords

BOCEPREVIR; INTERFERON; RIBAVIRIN; TELAPREVIR;

ADULT; COST EFFECTIVENESS ANALYSIS; DRUG COST; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; MAJOR CLINICAL STUDY; MONOTHERAPY; PREDICTION; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; TREATMENT RESPONSE; VIRUS HEPATITIS;

EID: 84863110460     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i23.3032     Document Type: Letter

References (19)

1. Tsubota A, Fujise K, Namiki Y, Tada N. Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol 2011; 17: 419-432
2. Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med 2012; 366: 273-275
3. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis 2012; 54: 96-104
4. Messori A, Del Santo F, Maratea D. First-line treatments for hepatitis C. Aliment Pharmacol Ther 2011; 33: 1383-1385
5. Maratea D, Messori A, Fadda V. Nationwide prediction of future expenditure for protease inhibitors in chronic hepatitis C. Dig Liver Dis 2012; 44: 86-87
6. Miyamura T, Kanda T, Nakamoto S, Wu S, Fujiwara K, Imazeki F, Yokosuka O. Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients. PLoS One 2011; 6: e28617
7. Cohen B. Vertex score big with hepatitis drug in America (September 2011). Available from: URL: http://www.hepctrust.org.uk/News_Resources/news/2011/September/Vertex score big with hepatitis drug in America accessed on 20 December 2011
8. Fojo T, Grady C. How much is life worth: cetuximab, nonsmall cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009; 101: 1044-1048
9. Krahn M, Gafni A. Discounting in the economic evaluation of health care interventions. Med Care 1993; 31: 403-418
10. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997; 11: 159-168
11. Torgerson DJ, Raftery J. Economic notes. Discounting. BMJ 1999; 319: 914-915
12. West RR, McNabb R, Thompson AG, Sheldon TA, Grimley Evans J. Estimating implied rates of discount in healthcare decision-making. Health Technol Assess 2003; 7: 1-60
13. Brouwer WB, Niessen LW, Postma MJ, Rutten FF. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 2005; 331: 446-448
14. Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ. Discounting and decision making in the economic evaluation of health-care technologies. Health Econ 2011; 20: 2-15
15. Anonymous. NICE changes discount rate methods (7 August 2011). Available from: URL: http://scharrheds.blogspot.com/2011/08/nice-changes-discount-rate-methods.html accessed on 20 December 2011
16. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-865
17. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004; 8: 3-4, 1-125
18. Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-205, 3
19. Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011; 15: 1-12, 1-210